Back
#1
37.6%
Top 58%
10.4%
Top 2%
7.4%
Top 1%
5.8%
Top 0.5%
5.8%
Top 8%
4.8%
Top 0.5%
4.4%
Top 61%
4.4%
Top 34%
2.2%
Top 1%
2.2%
Top 65%
0.8%
Top 5%
0.8%
Top 11%
0.8%
Top 27%
0.8%
Top 2%
0.5%
Top 11%
0.5%
Top 10%
0.5%
Top 7%
0.5%
Top 3%
0.5%
Top 15%
0.5%
Top 9%
0.5%
Ovarian carcinoma patients with a tumor BRCA-like genomic copy number aberration profile benefit from maintenance olaparib/bevacizumab therapy in the PAOLA-1 randomized controlled trial.
2023-06-01
oncology
Title + abstract only
View on medRxiv
Show abstract
BackgroundWe previously established an ovarian carcinoma (OC) BRCA-like genomic copy number aberration profile classifier ("BRCA-like classifier"), which identifies tumors with deleterious mutations and epigenetic alterations in the homologous recombination pathway (1). We explored whether the classifier may also be predictive for therapies targeting tumors with homologous recombination deficiency (HRD) such as olaparib, a PARP inhibitor with synthetic lethal interaction with HRD, in combination...
Predicted journal destinations
1
Cancers
57 training papers
2
PLOS ONE
1737 training papers
3
Frontiers in Oncology
34 training papers
4
Clinical Cancer Research
22 training papers
5
British Journal of Cancer
22 training papers
6
eLife
262 training papers
7
Cancer Medicine
17 training papers
8
Scientific Reports
701 training papers
9
Nature Communications
483 training papers
10
BMC Cancer
21 training papers
11
BMJ Open
553 training papers
12
Diagnostics
36 training papers
13
iScience
74 training papers
14
JAMA Network Open
125 training papers
15
International Journal of Cancer
18 training papers
16
PeerJ
46 training papers
17
Communications Medicine
63 training papers
18
Journal of Clinical Investigation
50 training papers
19
Cell Reports
25 training papers
20
Frontiers in Immunology
140 training papers
21
International Journal of Molecular Sciences
39 training papers